Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Novembro 2024 - 6:10PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, granted stock options to purchase 210,000
shares of Astria’s common stock on November 1, 2024 under Astria’s
2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock
Incentive Plan is used exclusively for the grant of equity awards
to individuals who were not previously an employee of Astria.
The options were granted as an inducement material to two
employees entering into employment with Astria in accordance with
Nasdaq Listing Rule 5635(c)(4). The options have an exercise price
of $11.32, which is equal to the closing price of Astria’s common
stock on November 1, 2024 (the “Grant Date”), and will vest over a
four-year period, with 25% of shares vesting on the first
anniversary of the employee’s employment start date (which preceded
the Grant Date) and the remaining shares vesting monthly on a
ratable basis over the following 36 months, subject to the
employee’s continued employment with Astria on such vesting dates.
The options are subject to the terms and conditions of the 2022
Inducement Stock Incentive Plan and the terms and conditions of an
award agreement covering the grant.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunologic diseases. Our lead
program, navenibart (STAR-0215), is a monoclonal antibody inhibitor
of plasma kallikrein in clinical development for the treatment of
hereditary angioedema. Our second program, STAR-0310, is a
monoclonal antibody OX40 antagonist in preclinical development for
the treatment of atopic dermatitis. Learn more about our company on
our website, www.astriatx.com, or follow us on X and Instagram
@AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104640225/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024